CXCL12 alone is insufficient for gliomagenesis in Nf1 mutant mice

Journal of Neuroimmunology

Volumn 224, Issue 1-2, 2010, Pages 108-113

  Sun, Tao ^a,c   Gianino, Scott M ^a,c   Jackson, Erin ^a,c   Piwnica Worms, David ^a,b,c   Gutmann, David H ^a,c   Rubin, Joshua B ^a,c  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c ST LOUIS CHILDREN S HOSPITAL   (United States)

Author keywords

AMD3100; CAMP; CXCL12; Glioma; NF1

Indexed keywords

CHEMOKINE RECEPTOR CXCR4; CYCLIC AMP; NEUROFIBROMIN; PLERIXAFOR; STROMAL CELL DERIVED FACTOR 1; CXCL12 PROTEIN, MOUSE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN TISSUE; CANCER STEM CELL; CARCINOGENESIS; CONTROLLED STUDY; GLIOBLASTOMA; GLIOMA; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; MOUSE; MOUSE MUTANT; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; SIGNAL TRANSDUCTION; TUMOR MICROENVIRONMENT; ANIMAL; BIOSYNTHESIS; BRAIN TUMOR; CELL LINE; CELL TRANSFORMATION; DISEASE MODEL; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; IMMUNOLOGY; METABOLISM; OPTIC NERVE GLIOMA; PHYSIOLOGY;

ANIMALS; BRAIN NEOPLASMS; CELL LINE; CELL TRANSFORMATION, NEOPLASTIC; CHEMOKINE CXCL12; DISEASE MODELS, ANIMAL; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICE; MICE, NEUROLOGIC MUTANTS; NEUROFIBROMIN 1; OPTIC NERVE GLIOMA; SIGNAL TRANSDUCTION;

EID: 77955085898     PISSN: 01655728     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jneuroim.2010.05.002     Document Type: Article

References (46)

1. Bajenaru M.L., Zhu Y., Hedrick N.M., Donahoe J., Parada L.F., Gutmann D.H. Astrocyte-specific inactivation of the neurofibromatosis 1 gene (NF1) is insufficient for astrocytoma formation. Mol. Cell. Biol. 2002, 22:5100-5113.
2. Bajenaru M.L., Hernandez M.R., Perry A., Zhu Y., Parada L.F., Garbow J.R., Gutmann D.H. Optic nerve glioma in mice requires astrocyte Nf1 gene inactivation and Nf1 brain heterozygosity. Cancer Res. 2003, 63:8573-8577.
3. Ballester R., Marchuk D., Boguski M., Saulino A., Letcher R., Wigler M., Collins F. The NF1 locus encodes a protein functionally related to mammalian GAP and yeast IRA proteins. Cell 1990, 63:851-859.
4. Banerjee D., Hegedus B., Gutmann D.H., Garbow J.R. Detection and measurement of neurofibromatosis-1 mouse optic glioma in vivo. Neuroimage 2007, 35:1434-1437.
5. Busek P., Stremenova J., Sedo A. Dipeptidyl peptidase-IV enzymatic activity bearing molecules in human brain tumors-good or evil?. Front. Biosci. 2008, 13:2319-2326.
6. Crump M.P., Gong J.H., Loetscher P., Rajarathnam K., Amara A., Arenzana-Seisdedos F., Virelizier J.L., Baggiolini M., Sykes B.D., Clark-Lewis I. Solution structure and basis for functional activity of stromal cell-derived factor-1; dissociation of CXCR4 activation from binding and inhibition of HIV-1. EMBO J. 1997, 16:6996-7007.
7. Daginakatte G.C., Gutmann D.H. Neurofibromatosis-1 (Nf1) heterozygous brain microglia elaborate paracrine factors that promote Nf1-deficient astrocyte and glioma growth. Hum. Mol. Genet. 2007, 16:1098-1112.
8. Dasgupta B., Dugan L.L., Gutmann D.H. The neurofibromatosis 1 gene product neurofibromin regulates pituitary adenylate cyclase-activating polypeptide-mediated signaling in astrocytes. J. Neurosci. 2003, 23:8949-8954.
9. DeClue J.E., Papageorge A.G., Fletcher J.A., Diehl S.R., Ratner N., Vass W.C., Lowy D.R. Abnormal regulation of mammalian p21ras contributes to malignant tumor growth in von Recklinghausen (type 1) neurofibromatosis. Cell 1992, 69:265-273.
10. Fan X., Zhang J., Zhang X., Yue W., Ma L. Acute and chronic morphine treatments and morphine withdrawal differentially regulate GRK2 and GRK5 gene expression in rat brain. Neuropharmacology 2002, 43:809-816.
11. Feldkamp M.M., Angelov L., Guha A. Neurofibromatosis type 1 peripheral nerve tumors: aberrant activation of the Ras pathway. Surg. Neurol. 1999, 51:211-218.
12. Goldhoff P., Warrington N.M., Limbrick D.D., Hope A., Woerner B.M., Jackson E., Perry A., Piwnica-Worms D., Rubin J.B. Targeted inhibition of cyclic AMP phosphodiesterase-4 promotes brain tumor regression. Clin. Cancer Res. 2008, 14:7717-7725.
13. Gottschall P.E., Yu X., Bing B. Increased production of gelatinase B (matrix metalloproteinase-9) and interleukin-6 by activated rat microglia in culture. J. Neurosci. Res. 1995, 42:335-342.
14. Gross S., Piwnica-Worms D. Real-time imaging of ligand-induced IKK activation in intact cells and in living mice. Nat. Meth. 2005, 2:607-614.
15. Gutmann D.H., Donahoe J., Brown T., James C.D., Perry A. Loss of neurofibromatosis 1 (NF1) gene expression in NF1-associated pilocytic astrocytomas. Neuropathol. Appl. Neurobiol. 2000, 26:361-367.
16. Hegedus B., Dasgupta B., Shin J.E., Emnett R.J., Hart-Mahon E.K., Elghazi L., Bernal-Mizrachi E., Gutmann D.H. Neurofibromatosis-1 regulates neuronal and glial cell differentiation from neuroglial progenitors in vivo by both cAMP- and Ras-dependent mechanisms. Cell Stem Cell 2007, 1:443-457.
17. Hegedus B., Banerjee D., Yeh T.H., Rothermich S., Perry A., Rubin J.B., Garbow J.R., Gutmann D.H. Preclinical cancer therapy in a mouse model of neurofibromatosis-1 optic glioma. Cancer Res. 2008, 68:1520-1528.
18. Kleihues P., Louis D.N., Scheithauer B.W., Rorke L.B., Reifenberger G., Burger P.C., Cavenee W.K. The WHO classification of tumors of the nervous system. J. Neuropathol. Exp. Neurol. 2002, 61:215-225. discussion 226-219.
19. Kluwe L., Hagel C., Tatagiba M., Thomas S., Stavrou D., Ostertag H., von Deimling A., Mautner V.F. Loss of NF1 alleles distinguish sporadic from NF1-associated pilocytic astrocytomas. J. Neuropathol. Exp. Neurol. 2001, 60:917-920.
20. Lambeir A.M., Proost P., Durinx C., Bal G., Senten K., Augustyns K., Scharpe S., Van Damme J., De Meester I. Kinetic investigation of chemokine truncation by CD26/dipeptidyl peptidase IV reveals a striking selectivity within the chemokine family. J. Biol. Chem. 2001, 276:29839-29845.
21. Ligon K.L., Alberta J.A., Kho A.T., Weiss J., Kwaan M.R., Nutt C.L., Louis D.N., Stiles C.D., Rowitch D.H. The oligodendroglial lineage marker OLIG2 is universally expressed in diffuse gliomas. J. Neuropathol. Exp. Neurol. 2004, 63:499-509.
22. Listernick R., Louis D.N., Packer R.J., Gutmann D.H. Optic pathway gliomas in children with neurofibromatosis 1: consensus statement from the NF1 Optic Pathway Glioma Task Force. Ann. Neurol. 1997, 41:143-149.
23. Listernick R., Ferner R.E., Liu G.T., Gutmann D.H. Optic pathway gliomas in neurofibromatosis-1: controversies and recommendations. Ann. Neurol. 2007, 61:189-198.
24. Lois C., Hong E.J., Pease S., Brown E.J., Baltimore D. Germline transmission and tissue-specific expression of transgenes delivered by lentiviral vectors. Science 2002, 295:868-872.
25. Martin G.A., Viskochil D., Bollag G., McCabe P.C., Crosier W.J., Haubruck H., Conroy L., Clark R., O'Connell P., Cawthon R.M., et al. The GAP-related domain of the neurofibromatosis type 1 gene product interacts with ras p21. Cell 1990, 63:843-849.
26. McManus M.F., Chen L.C., Vallejo I., Vallejo M. Astroglial differentiation of cortical precursor cells triggered by activation of the cAMP-dependent signaling pathway. J. Neurosci. 1999, 19:9004-9015.
27. McQuibban G.A., Butler G.S., Gong J.H., Bendall L., Power C., Clark-Lewis I., Overall C.M. Matrix metalloproteinase activity inactivates the CXC chemokine stromal cell-derived factor-1. J. Biol. Chem. 2001, 276:43503-43508.
28. Mizokami Y., Kajiyama H., Shibata K., Ino K., Kikkawa F., Mizutani S. Stromal cell-derived factor-1alpha-induced cell proliferation and its possible regulation by CD26/dipeptidyl peptidase IV in endometrial adenocarcinoma. Int. J. Cancer 2004, 110:652-659.
29. Nishimoto M., Furuta A., Aoki S., Kudo Y., Miyakawa H., Wada K. PACAP/PAC1 autocrine system promotes proliferation and astrogenesis in neural progenitor cells. Glia 2007, 55:317-327.
30. Phillips R.A., Hunter J.L., Eccleston J.F., Webb M.R. The mechanism of Ras GTPase activation by neurofibromin. Biochemistry 2003, 42:3956-3965.
31. Polyak K., Haviv I., Campbell I.G. Co-evolution of tumor cells and their microenvironment. Trends Genet. 2009, 25:30-38.
32. Rubin J.B. Chemokine signaling in cancer: one hump or two?. Semin. Cancer Biol. 2009, 19:116-122.
33. Rubin J.B., Gutmann D.H. Neurofibromatosis type 1 - a model for nervous system tumour formation?. Nat. Rev. Cancer 2005, 5:557-564.
34. Rubin J.B., Kung A.L., Klein R.S., Chan J.A., Sun Y., Schmidt K., Kieran M.W., Luster A.D., Segal R.A. A small-molecule antagonist of CXCR4 inhibits intracranial growth of primary brain tumors. Proc. Natl Acad. Sci. USA 2003, 100:13513-13518.
35. Saugstad J.A., Marino M.J., Folk J.A., Hepler J.R., Conn P.J. RGS4 inhibits signaling by group I metabotropic glutamate receptors. J. Neurosci. 1998, 18:905-913.
36. Suh J., Lu N., Nicot A., Tatsuno I., DiCicco-Bloom E. PACAP is an anti-mitogenic signal in developing cerebral cortex. Nat. Neurosci. 2001, 4:123-124.
37. Tong J., Hannan F., Zhu Y., Bernards A., Zhong Y. Neurofibromin regulates G protein-stimulated adenylyl cyclase activity. Nat. Neurosci. 2002, 5:95-96.
38. Vallejo I., Vallejo M. Pituitary adenylate cyclase-activating polypeptide induces astrocyte differentiation of precursor cells from developing cerebral cortex. Mol. Cell. Neurosci. 2002, 21:671-683.
39. Warrington N.M., Woerner B.M., Daginakatte G.C., Dasgupta B., Perry A., Gutmann D.H., Rubin J.B. Spatiotemporal differences in CXCL12 expression and cyclic AMP underlie the unique pattern of optic glioma growth in neurofibromatosis type 1. Cancer Res. 2007, 67:8588-8595.
40. Warrington, N.M., Gianino, S.M., Jackson, E., Gribben, E., Goldhoff, P., Garbow, J.R., Piwnica-Worms, D., Gutmann, D.H., Rubin, J.B., in press. Cyclic AMP suppression is sufficient to induce gliomagenesis in amouse model of Neurofibromatosis-1. Cancer Res.
41. Williams V.C., Lucas J., Babcock M.A., Gutmann D.H., Korf B., Maria B.L. Neurofibromatosis type 1 revisited. Pediatrics 2009, 123:124-133.
42. Woerner B.M., Warrington N.M., Kung A.L., Perry A., Rubin J.B. Widespread CXCR4 activation in astrocytomas revealed by phospho-CXCR4-specific antibodies. Cancer Res. 2005, 65:11392-11399.
43. Yamada T., Yoshiyama Y., Sato H., Seiki M., Shinagawa A., Takahashi M. White matter microglia produce membrane-type matrix metalloprotease, an activator of gelatinase A, in human brain tissues. Acta Neuropathol. 1995, 90:421-424.
44. Yang L., Jackson E., Woerner B.M., Perry A., Piwnica-Worms D., Rubin J.B. Blocking CXCR4-mediated cyclic AMP suppression inhibits brain tumor growth in vivo. Cancer Res. 2007, 67:651-658.
45. Zaruba M.M., Theiss H.D., Vallaster M., Mehl U., Brunner S., David R., Fischer R., Krieg L., Hirsch E., Huber B., Nathan P., Israel L., Imhof A., Herbach N., Assmann G., Wanke R., Mueller-Hoecker J., Steinbeck G., Franz W.M. Synergy between CD26/DPP-IV inhibition and G-CSF improves cardiac function after acute myocardial infarction. Cell Stem Cell 2009, 4:313-323.
46. Zhu Y., Harada T., Liu L., Lush M.E., Guignard F., Harada C., Burns D.K., Bajenaru M.L., Gutmann D.H., Parada L.F. Inactivation of NF1 in CNS causes increased glial progenitor proliferation and optic glioma formation. Development 2005, 132:5577-5588.